An online tool for predicting ovarian reserve based on AMH level and age: A retrospective cohort study

Yong Han1,2†, Huiyu Xu3,4,5,6†, Guoshuang Feng7†, Haiyan Wang3,4,5,6, Kannan Alpadi8, Lixue Chen3,4,5,6, Mengqian Zhang3,4,5,6 and Rong Li3,4,5,6*

1Department of Thoracic Surgery, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, China, 2Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang, China, 3Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China, 4Key Laboratory of Assisted Reproduction, Ministry of Education, Beijing, China, 5National Clinical Research Center for Obstetrics and Gynecology, Beijing, China, 6Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Beijing, China, 8The Predict Health, Houston, TX, United States

Purpose: To establish a more convenient ovarian reserve model with anti-Müllerian hormone (AMH) level and age (the AA model), with blood samples taken at any time in the menstrual cycle.

Methods: We have established this AA model for predicting ovarian reserve using the AMH level and age. The outcome variable was defined as poor ovarian response (POR) with <5 oocytes retrieved during assisted reproductive technology treatment cycles. Least Absolute Shrinkage and Selection Operator logistic regression with 5-fold cross validation methods was applied to construct the model, and that with the lowest scaled log-likelihood was selected as the final one.

Results: The areas under the receiver operating characteristic curve for the training, inner, and external validation sets were 0.862, 0.843, and 0.854 respectively. The main effects of AMH level and age contributing to the prediction of POR were 95.3% and 1.8%, respectively. The incidences of POR increased with its predicted probability in both the model building and in external validation datasets, indicating its stability. An online website-based tool for assessing the score of ovarian reserve (http://121.43.113.123:9999) has been developed.

Conclusions: Based on external validation data, the AA model performed well in predicting POR, and was more cost-effective and convenient than our previous published models.

KEYWORDS
age, anti-müllerian hormone (AMH), online tool, ovarian reserve, predict
Introduction

Although the number and quality of ovarian follicles change profoundly with a woman’s age, the individual process of ovarian aging has not yet attracted enough attention (1). To our knowledge, most women do not know about the heterogeneity that is documented for ovarian reserve and ovarian aging. Irregular cycles and the menopause are easily identified, but fertility is already extremely low when these signs actually appear, leaving limited interventions available (2, 3). The decline of natural fertility occurs earlier, but often cannot be recognized directly (1). Almost 20% of reproductive-aged women attending infertility clinics show signs of premature ovarian aging. Such increased female infertility results from both the lack of knowledge on the heterogeneity of ovarian reserve/ovarian aging, and the tendency to delay childbearing in modern societies.

Ovarian reserve refers to the number of primordial follicles in the ovary that have the capacity to develop into mature oocytes (4–6). It is acknowledged that the age-related decrease in ovarian reserve is linked to the gradual loss of primordial follicles (1, 7), when follicular atresia takes place (8, 9). Anti-Müllerian hormone (AMH) is secreted by granulosa cells from preantral and small antral follicles (10, 11). One role of this hormone is to inhibit the recruitment of primordial follicles (12–14), so it is closely linked to ovarian reserve. The level of AMH reflects the number of gonadotropin (Gn)-independent small growing follicles (15), and the better the ovarian reserve is, the more such follicles there are.

We have already established two models for predicting ovarian reserve: a four-predictor AAFA (AMH–antral follicle count (AFC)–FSH–age) model (16), and a three-predictor AFA (AMH–FSH–age) model (17). The advantage of the AFA model is that on one hand, it does not need the AFC, only two serum hormone predictors and age, but the area under the curve (AUC) of the receiver operating curve (ROC) is as good as the AAFA model (17). However, blood sampling for FSH, the predictor in both models, needs to be done specifically on day 2 of the menstrual cycle, which limits the clinical application of the AFA model in general medical examinations. In this study, considering the known correlation between AMH and FSH levels, we aimed to establish an ‘AA model’ using only AMH and age, so that blood sampling could be carried out at any time in the menstrual cycle for assessing ovarian reserve.

Materials and methods

Subjects

This was a retrospective observational cohort study in Peking University Third Hospital. In all, 4796 standard gonadotropin releasing hormone (GnRH) antagonist cycles from 2017 to 2018 were selected according to inclusion and exclusion criteria for model building based on the datasets used in our previous studies (16, 17). Then, 5009 standard GnRH antagonist cycles from 2019 without sample selection were used for external validation. The inclusion criteria in the 2017-2018 data included: 1) female patients aged 20-45 y; 2) body mass index (BMI) ≤30 kg/m²; 3) previous attempted cycles ≤2. The exclusion criteria for the 2017-2018 data included: 1) treated or untreated ovarian cysts; 2) previous ovarian surgery; 3) polycystic ovary syndrome (PCOS); 4) previous metabolic or endocrinological diseases; 5) previous tuberculosis; 6) mild ovarian stimulation protocols; and 7) women with chromosomal abnormalities. The basic characteristics of the 2017-2018 model building data and the 2019 external validation data are shown in Table 1. The dataset used in this study contains deidentified data, so the need for informed consent from the patients was waived and institutional review board approval was not needed, thereby conforming to the Helsinki Declaration (18).

Sampling and endocrine assays

Venous blood was collected using serum separation tubes that were inverted immediately and mixed five times, left at room temperature for 30 min, centrifuged at 1700 g for 10 min,
and the serum retained for hormone measurements. The serum AMH level was measured on any day of the menstrual cycle, while the serum FSH level was measured on day 2. The assays and quality controls for FSH and AMH were as described (16, 17).

**Statistical analysis**

Research data in this study were collected from the patient registry database in Peking University Third Hospital. All the analyses in this study were performed using SAS JMP Pro (version 14.2; SAS Institute, Cary, NC, USA), and \( p < 0.05 \) was considered statistically significant. Normally distributed variables are presented as the mean and standard deviation, while variables not normally distributed are presented as the median and quartiles. POR (<5 oocytes retrieved during ovarian stimulation) was used as the outcome variable for this AA model, which was the same as previously used for our AFA (17) and AAFA (16) models. Age and AMH were included into our modeling as categorical predictive variables. Least Absolute Shrinkage and Selection Operator (LASSO) logistic regression with 5-fold cross validation was applied to construct the model, and that with the lowest scaled log-likelihood was selected. The main effect of each predicting variable measures the variation over the distribution of \( x_j \) in the mean POR, which reflects the relative contribution of the variable alone to the model. Accuracy of the predictive AA model was assessed using the area under the ROC curve (AUC), sensitivity and specificity, with 95% confidence interval (CI) values. We also used the AUC and Venn diagrams to compare the accuracy of the AA model with the AFA and AAFA models (16, 17). Ranking of ovarian reserve from good to poor were based on the predicted probability of POR from low to high. Ovarian reserve, [score (N) = (1-predicted POR probability) \times 100].

**Results**

For building the AA model, first, the continuous variables of AMH and age were transformed into categorical variables, and the classification was mainly based on prior data exploration, as indicated in Supplementary Figure 1. To minimize the potential collinearity of variables measured from the same patient and over-fitting of variables, the LASSO logistic regression was used. In the 2017-2018 model-building dataset, we used five-fold cross-checking for internal validation. The AA model with the lowest scaled log-likelihood was finally selected. The AUCs for the training and internal validation sets were 0.862 and 0.843, respectively.

The effects of each predicting variable on the POR were listed in Table 2. Compared with the AMH control group (AMH ≤0.2 ng/ml), the parameter estimates decreased with AMH concentrations, indicating the decreasing probability of POR with increased AMH levels, which is of statistical significance. Compared with the age control group (≤30 y), the parameter estimates increased with age group, indicating the increasing probability of POR with increased age. The main effects of AMH and age contributing to this model were 95.3% and 1.8% respectively. The actual incidences and predicted probabilities of POR in each group of the 60 groups in 2017-2018 data are listed in Table 3. This table can help us understand the performance of our model. Ideally, the predicted probability of each group should be exactly the same as the actual incidence.

We collected additional 2019 data for external validation of this AA model. The difference from the 2017-2018 data is that

**TABLE 2  The effects of each predicting variable on POR using AA model.**

| Variables | Parameter estimation | Standard error | Wald \( \chi^2 \) | \( p \) value |
|-----------|----------------------|----------------|-------------------|----------------|
| AMH [(3,~) vs [0,0.2]] | -4.335 | 0.234 | 343.3393 | <.0001 |
| AMH [(2.3] vs [0,0.2]] | -3.8031 | 0.252 | 227.7726 | <.0001 |
| AMH [(1.8,2] vs [0,0.2]] | -3.2347 | 0.3292 | 96.5493 | <.0001 |
| AMH [(1.4,1.8] vs [0,0.2]] | -2.883 | 0.245 | 138.4393 | <.0001 |
| AMH [(1.2,1.4] vs [0,0.2]] | -2.3813 | 0.2546 | 87.4919 | <.0001 |
| AMH [(1.0,1.2] vs [0,0.2]] | -2.2321 | 0.2458 | 82.4412 | <.0001 |
| AMH [(0.6,1.0] vs [0,0.2]] | -1.6751 | 0.2147 | 60.8473 | <.0001 |
| AMH [(0.4,0.6] vs [0,0.2]] | -0.8742 | 0.2357 | 13.7592 | <.0002 |
| AMH [(0.2,0.4] vs [0,0.2]] | -0.5727 | 0.2406 | 5.6686 | 0.0173 |
| Age [(42,~) vs [0,30]] | 0.807 | 0.2303 | 12.2579 | 0.0005 |
| Age [(39,42] vs [0,30]] | 1.0434 | 0.1711 | 37.1979 | <.0001 |
| Age [(37,39] vs [0,30]] | 0.5885 | 0.1794 | 10.7573 | 0.001 |
| Age [(35,37] vs [0,30]] | 0.4299 | 0.1705 | 6.3561 | 0.0117 |
| Age [(30,35] vs [0,30]] | 0.28 | 0.14 | 4.06 | 0.04 |
these data did not undergo data selection, and all standard GnRH antagonist protocols were included. Figure 1 shows the incidence of POR and predicted probability of POR in model-building data (2017-2018 data), which excluded women with ovarian abnormalities and endocrinopathies, and the external validation data (2019 data) including all standard GnRH antagonist protocols. Figure 1 also contributes to the understanding of the performance of our model. Ideally, the predicted probability of each group should be exactly the same as the actual incidence. As shown, the prevalence of POR increased with its predicted probability in our AA model. For example, in women with the worst ovarian reserve, with a predicted POR probability of 0.8-0.85, the prevalence of POR was 20/21 in 2019 data vs 45/54 in the 2017-2018 data. The incidences and

| Age classification (years) | ≤30 | (30, 35] | (35, 37] | (37, 39] | (39, 42] | >42 |
|---------------------------|-----|---------|---------|---------|---------|-----|
| AMH classification (ng/ml) |     |         |         |         |         |     |
| (3.67, 4.75]            | 2.3% (2.4%) | 4.2% (3.2%) | 0.8% (3.7%) | 4.2% (4.3%) | 4.6% (6.6%) | 6.3% (5.3%) |
| (2.37, 3.67]            | 4.1% (4.1%) | 5.6% (5.4%) | 7.1% (6.2%) | 6% (7.1%) | 7.9% (10.8%) | 25.0% (8.7%) |
| (1.82, 2.37]            | 13.3% (7.0%) | 17% (9.1%) | 9.4% (10.4%) | 0% (11.9%) | 25.0% (17.6%) | 50.0% (14.4%) |
| (1.41, 1.82]            | 12.6% (9.7%) | 11.687% (12.4%) | 13.5% (14.1) | 19.34% (16.2%) | 16.4% (23.3%) | 18.2% (19.3%) |
| (1.21, 1.4]             | 10.0% (15.0%) | 20.3% (19.0%) | 16.2% (21.4%) | 16.7% (24.1%) | 42.3% (33.4%) | 33.3% (28.4%) |
| (1.01, 1.2]             | 9.9% (17.0%) | 20.0% (21.4%) | 21.4% (24.0%) | 40.0% (27.0%) | 47.8% (36.8%) | 10.0% (31.5%) |
| (0.61, 0.81]            | 30.4% (26.4%) | 35.3% (32.2%) | 33.9% (35.5%) | 40.3% (39.2%) | 37.5% (50.4%) | 48.5% (44.5%) |
| (0.40, 0.61]            | 50.0% (44.4%) | 44.4% (51.4%) | 48.0% (55.1%) | 54.6% (58.9%) | 70.6% (69.4%) | 72.7% (64.1%) |
| (0.20, 0.4]             | 54.6% (51.9%) | 56.1% (58.9%) | 73.7% (62.4%) | 70.4% (66.0%) | 81.0% (75.4%) | 58.1% (70.7%) |
| ≤0.2                    | 56.7% (65.5%) | 75.0% (71.7%) | 82.1% (84.6%) | 76.9% (77.5%) | 86.7% (84.4%) | 79.2% (81.1%) |

TABLE 3 The actual incidence (predicted probability) of POR.

POR, poor ovarian response.
predicted probabilities of POR in 60 groups in the 2019 data are shown in Supplementary Table 1.

The performance of this AA ovarian reserve model we established here was compared with those of the AAFA (16), and AFA (17) models we built previously, using 2019 external validation data. Figure 2A demonstrates the AUCs and the differences between these three models. The AUCs of the AFA and AA models were significantly higher than in the AAFA model, while the difference between the AFA and AA model in the AUCs was not significant. The Venn diagram in Figure 2B shows the predicted negative and positive POR estimates of the three models in this 2019 external verification data. The numbers within circles indicate the predicted positive cases, while those outside the circles indicate the predicted negative cases. There were 1271 overlapping positive predicted cases of POR in the three models, and 3055 overlapping predicted negative cases of POR. The overlapping negative and positive predicted incidences in all three models accounted for 86.4% of the total 5009 samples in the 2019 data.

The above results showed that the AAFA model and the AFA model were not better than the AA model. We wondered whether it was caused by the different grouping standards of the independent variables in different models. Therefore, we explored the use of the same grouping criteria for AMH and age in the AA model and reassessed the AFA and AAFA models. The 2017-2018 data were used as a training set, and the 2019 data were used as a validation set. The estimation parameters of the improved AAFA and AFA models are shown in Supplementary Tables 2, 3, respectively. The performances of all three models in terms of the AUC, sensitivity, and specificity are shown in Table 4. No differences in terms of AUC, sensitivity, and specificity were discovered, demonstrated by overlapping of their 95% confidence intervals. The ovarian reserve scores evaluated by AA model, improved AAFA and AFA models are almost the same, and the raw data and the ovarian reserve scores are shown in Supplementary Table 4.

The contribution made by age is small, does it mean that AMH alone can be used to assess ovarian reserve? In addition, whether it is possible to use AMH as a continuous variable rather than transforming it into a categorical variable, we made the following comparison. As shown in Table 5, we constructed four models: model 1 with AMH + age as categorical variables; model 2 with AMH alone as a categorical variable; model 3 with AMH + age as continuous variables; model 4 with AMH alone as a continuous variable. As shown in Table 5, the AUCs of the four models were similar, but the sensitivities were lower in models 3 and 4 with large variations in sensitivity (i.e., the true positive rate) in the training and validation sets. Thus, AMH as a continuous variable was not optimal.

As to whether age is needed in ovarian reserve assessment. The aim of establishing this model is not only to predict POR or not (two groups), but also to rank the ovarian reserve of individuals into many subgroups according to the predicted probability of POR. AUC is only used to evaluate the performance of predicting POR or not, based on a predicted POR probability of 50% or not. In Table 3, we demonstrated the predicted probability and incidences of POR in all 60 groups in the 2019 external validation data. Obviously, the predicted POR probability and incidences of POR in different age groups within the same AMH group were significantly different. According to our ovarian reserve score, we ranked the ovarian reserve of individuals into many subgroups based on the predicted probability of POR, not just two groups of POR or not. Therefore, considering the clinical application, we chose to use both AMH and age as categorical variables for model building. Table 3 showed that among the 60 groups, the predicted probabilities of POR were close to their incidences in each group. The same trend was also shown in Figure 1. These results indicated that our model 1 using AMH and age as categorical variables is of great practical value. Thus, we chose the model 1 as our final AA model.
TABLE 4 The AUCs, sensitivity and specificity of AA, improved AAFA and AFA models in training (2017-2018 data) and external validation (2019 data) using the same grouping criteria.

| Measures       | AA model                                                                 | AAFA model                                                                            | AFA model                                                                 |
|----------------|-------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
|                | training set                | validation set                                                                         | training set                | validation set                                                                         | training set                | validation set                                                                         |
| ROC (95% CI)   | 0.860 (0.850–0.870)         | 0.854 (0.844 – 0.864)                                                                 | 0.870 (0.858–0.881)         | 0.882 (0.848–0.908)                                                                 | 0.861 (0.848–0.872)         | 0.875 (0.837–0.905)                                                                 |
| Sensitivity (95% CI) | 0.485 (0.451–0.520)                         | 0.462 (0.423–0.500)                                                                  | 0.463 (0.436–0.490)         | 0.434 (0.357–0.516)                                                                  | 0.412 (0.386–0.439)         | 0.441 (0.363–0.523)                                                                  |
| Specificity (95% CI) | 0.941 (0.933–0.948)                       | 0.961 (0.955,0.966)                                                                  | 0.966 (0.962–0.970)         | 0.958 (0.942–0.969)                                                                  | 0.968 (0.963–0.971)         | 0.959 (0.943–0.971)                                                                  |

Next, we constructed a website-based ovarian reserve assessment tool according to the AA model, and the improved AAFA and AFA models (http://121.43.113.123:9999) (Figure 3). The input information also includes age at menarche, menstrual cycle duration and other related basic information, which are designed for further improvement of this software. The result display will give the user an estimate of their ovarian reserve, up to a full score of 100 points. The higher the score, the better the predicted ovarian reserve [score (N) = (1–predicted POR probability) ×100]. The grouping criteria of ovarian reserve from A to D are consistent with our previous studies (16, 17).

Discussion

Here we have established an optimized two-indicator AA model for assessing ovarian reserve, which has the advantage of being applicable at any time during the menstrual cycles compared with our previous AFA (17) and AAFA (16) models. Moreover, with fewer indicators, the cost is lower and the performance of the AA model is similar to the improved AFA and AAFA models. In the same 2019 external validation dataset using the same grouping criteria, the AUCs of AA, improved AAFA and improved AFA models were 0.854 (0.844–0.864), 0.882 (0.848–0.908), and 0.875 (0.837–0.905), indicating that there are no significant differences among these models.

Assisted reproductive technology (ART) approaches are often ineffective in women with diminished ovarian reserve (DOR) (2, 3), thus increasing the economic, medical and social costs of ART. The advent of our online tool will be of great help for reproductive-aged women to arrange their childbearing plans according to their own ovarian reserve status, and might help in reducing the incidence of infertility by giving a timely warning of DOR. Besides, our online ovarian reserve assessment tool could not only help a reproductive woman know about her ovarian reserve status but might also be applied to infertility related medical research. For example, the role of the DNA fragmentation index (DFI) on male fertility is inconclusive (19–21), because of the compounding factors such as DOR. Using our online tool for estimating ovarian reserve, this acknowledged factor for female fertility will be controlled, so the role of DFI in the fertility of couples will be clarified.

How to transform the continuous variable of AMH level into a categorical variable according to cut-offs was a critical decision for our analysis. First, it is mainly based on data exploration, that is, to explore the best grouping method according to the relationship between independent variables and the outcome variable. Taking the AMH level as an example, we initially divided it into many groups with an interval of 0.1ng/ml, and then pooled groups with similar incidences of POR. Second, to pool those groups, in addition to the data exploration, the clinical significance of these categories needs to be considered. Third, it is very important to ensure that there are enough cases in each category to avoid unstable results. Considering the above three points, we finally divided the AMH level into 10 categories.

The dynamic changes in AMH levels and in the numbers of primordial follicles (i.e., ovarian reserve) with age were subjects in our recent reviews (22–25). The number of primordial follicles drops rapidly before the initial expression of AMH in the fetus, at 36 gestational weeks (11), and then slows down after the advent of AMH secretion. After menarche, both the numbers of primordial follicles and AMH levels fluctuate with age, and the rate of this fluctuation is associated with the number of primordial follicles at birth. As the number of primordial follicles decreases, the AMH level also decreases. This indicates that the AMH level is a good indicator of ovarian reserve, and a decrease in AMH level may be an early warning of DOR. Therefore, it is important to monitor AMH levels regularly to detect DOR early and provide timely treatment.

TABLE 5 Comparison of different models using AMH or not, or using AMH as categorical variable or not.

| Model-1 (AMH and age as categorical variables) | Model-2 (AMH as categorical variable) | Model-3 (AMH and age as continuous variables) | Model-4 (AMH as continuous variable) |
|-----------------------------------------------|---------------------------------------|-----------------------------------------------|---------------------------------------|
| Training                                      | Validation                            | Training                                      | Validation                            |
| AUC                                           | 0.86                                  | 0.85                                          | 0.85                                  | 0.86                                  | 0.86                                  | 0.86                                  |
| Sensitivity                                   | 0.49                                  | 0.42                                          | 0.48                                  | 0.35                                  | 0.17                                  | 0.35                                  |
| Specificity                                   | 0.94                                  | 0.97                                          | 0.95                                  | 0.98                                  | 0.99                                  | 0.98                                  |

Training, training set using 2017-2018 data; Validation, Validation set using 2019 data.
follicles and the AMH level decrease with age. Therefore, AMH has increasingly been regarded as the best marker for ovarian reserve in recent years. The main effect of AMH in our AA model is 95.3%, and age contributes to only 1.8%, indicating the key role of AMH in assessing ovarian reserve.

Why do we define POR using the number of oocytes retrieved rather than the number of MII oocytes and 2PN fertilized embryos as the outcome variable for ovarian reserve assessment? Our results indicate that AMH and age as categorical variables can also predict the number of MII oocytes and 2PN fertilized embryos, but with lower AUC and lower sensitivity (i.e., the true positive rate) (Supplementary Table 5). This might because the AMH level and age mainly reflect the basic status of ovarian reserve, but when ART progresses, the numbers of MII oocytes and 2PN fertilized embryos are not only affected by ovarian reserve, but also other factors, for example, the FSH receptor status and male factors. Therefore, we suppose that the outcome variable of POR defined by the number of oocytes retrieved might be a better outcome variable for ranking ovarian reserve among reproductive-age women. Other variables such as the number of aspirated follicles on the day of oocyte retrieval might be a good candidate for outcome variable, which needs further investigation.

As to the effectiveness with extreme values of AMH, one of the reasons we chose to build this model using AMH and age as categorical variables is its stability, as described above. Furthermore, we have also developed a PCOS screening model (26) (http://121.43.113.123:8888/). A woman with an extremely high AMH level could first be screened for PCOS, and then be assessed for ovarian reserve status using our models.

Limitations of the study

As to the limitations of our study, first, because the AA model is divided into 60 subgroups, we found that the predicted probability of POR in some groups differed from the actual incidence of POR as listed in Table 4. This might reflect the small sample sizes in certain subgroups, but through expanding sample sizes and re-classification of the predictors, we believe that the performances of the AA, AFA
and AAFA models will be improved in the future. Second, representativeness was an issue. Our original hypothesis was that the order of ovarian reserve from good to poor in patients undergoing GnRH antagonist ovarian stimulation would reflect the order of ovarian reserve from good to poor in the general population; however, this assumption needs to be tested. However, ovarian reserve can not be tested noninvasively, posing ethical challenges for further verification of our AA ovarian reserve model in the general population.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by The Human Reproductive Ethics Committee of Peking University Third Hospital. The patients/participants provided their written informed consent to participate in this study.

Author contributions

YH, HX and GF contributed to manuscript drafting and revising. YH, HX, GF, HW, LC, and KA contributed to data analysis and interpretation. HX, HW, LC, and MZ prepared figures and tables. RL contributed to the conception of the study, manuscript revising and final approval. All authors reviewed the manuscript.

Funding

This study was supported by the National Key Research and Development Program of China (Grant No. 2018YFC1002104, 2018YFC1002106); the Innovation & Transfer Fund of Peking University Third Hospital (Grant No. BYSYZH2020102, BYSYZH2021104); the National Natural Science Foundation of China for Distinguished Young Scholars (Grant No. 81925013); the Major National R&D Projects of China (Grant No. 2017ZX09304012-012); National Natural Science Foundation of China (Grant No. 81771650); the Capital Health Research and Development of Special Project (Grant No. 2018-1-4091).

Acknowledgments

We thank James Cummins, PhD, from LiwenBianji, Edanz Group China (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.

Conflict of interest

Author KA is employed by The Predict Health. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022.946123/full#supplementary-material

References

1. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: Mechanisms and clinical consequences. Endocr Rev (2009) 30:465–93. doi: 10.1210/er.2009-0086
2. Habbema JD, Eijkemans MJ, Nargund G, Beets G, Leridon H, Te Velde ER. The effect of in vitro fertilization on birth rates in western countries. Hum Reprod (2009) 24:1414–9. doi: 10.1093/humrep/dev004
3. Hoorens S, Gallo F, Cave JA, Grant JC. Can assisted reproductive technologies help to offset population ageing? an assessment of the demographic and economic impact of ART in Denmark and UK. Hum Reprod (2007) 22:2471–5. doi: 10.1093/humrep/dem181
4. Qiao J, Wang ZB, Feng HL, Miao YL, Wang Q, Yu Y, et al. The root of reduced fertility in aged women and possible therapeutic options: current status and future perspectives. Mol Aspects Med (2014) 38:54–85. doi: 10.1016/j.mam.2013.06.001
5. Lass A. Assessment of ovarian reserve: is there still a role for ovarian biopsy in the light of new data? Hum Reprod (2004) 19:467–9. doi: 10.1093/humrep/deh118
6. Broekmans FJ, Kwee J, Hendrikx DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update (2006) 12:685–718. doi: 10.1093/humupd/dmi034
7. de Bruin JP, Dorland M, Spok ER, Posthuma G, van Haalten M, Looman CWN, et al. Age-related changes in the ultrastructure of the resting follicle pool in human ovaries. **Biol Reprod** (2004) 70:419–24. doi:10.1095/biolreprod.103.015784

8. Depalo R, Nappi L, Loverro G, Bettocchi S, Caruso ML, Valentini AM, et al. Evidence of apoptosis in human primordial and primary follicles. **Hum Reprod** (2003) 18:2678–82. doi:10.1093/humrep/deg607

9. Glamocija V, Vlodovic K, Saraga-Babic M, Baranovic A, Sapunar D. Apoptosis and active caspase-3 expression in human granulosa cells. **Fertil Steril** (2005) 83:426–31. doi:10.1016/j.fertnstert.2004.06.075

10. Broer SL, Broekmans FJ, Laven JS, Fauser BC. Anti-mullerian hormone: ovarian reserve testing and its potential clinical implications. **Hum Reprod Update** (2014) 20:688–701. doi:10.1093/humupd/dmu020

11. Rajpert-De Meyts E, Jorgensen N, Graem N, Muller J, Cate RL, Skakkebaek NE. Expression of anti-mullerian hormone during normal and pathological gonadal development: Association with differentiation of sertoli and granulosa cells. J Clin Endocrinol Metab (1999) 84:3836–44. doi:10.1210/jc.84.10.3836

12. Durlinger AL, Kramer P, Karls B, de Jong FH, Uilenbroek JT, Grootegoed JA, et al. Control of primordial follicle recruitment by anti-mullerian hormone in the mouse ovary. **Endocrinology** (1999) 140:5789–96. doi:10.1210/endo.140.12.7204

13. Durlinger AL, Gruijters MJ, Kramer P, Karls B, Ingraham HA, Nachtigal MW, et al. Anti-mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. **Endocrinology** (2002) 143:1076–84. doi:10.1210/endo.143.3.8691

14. Carlsson IB, Scott JE, Visser JA, Ritvos O, Themmen AP, Hovatta O. Anti-mullerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. **Hum Reprod** (2006) 21:2223–7. doi:10.1093/humrep/dei165

15. Fanchin R, De Pawm K, Taieb J, Cavagna M, Feyerisen E, Dzik A. Lack of AMH response to EFOR suggests that AMH production is gonadotropin-independent in adult women. **Fertil Steril** (2005) 84:5424–5. doi:10.1016/j.fertnstert.2005.07.1108

16. Xu H, Feng G, Wang H, Han Y, Yang R, Song Y, et al. A novel mathematical model of true ovarian reserve assessment based on predicted probability of poor ovarian response: a retrospective cohort study. **J Assist Reprod Genet** (2020) 37:963–72. doi:10.1007/s10815-020-01700-1

17. Xu H, Shi L, Feng G, Xiao Z, Chen L, Li R, et al. An ovarian reserve assessment model based on anti-mullerian hormone levels, follicle-stimulating hormone levels, and age: Retrospective cohort study. **J Med Internet Res** (2020) 22:e19096. doi:10.2196/19096

18. World Medical A. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. **JAMA** (2013) 310:2191–4. doi:10.1001/jama.2013.281053

19. Sun TC, Zhang Y, Li HT, Liu XM, Yi DX, Tian L, et al. Sperm DNA fragmentation index, as measured by sperm chromatin dispersion, might not predict assisted reproductive outcome. **Taiwan J Obstet Gynecol** (2018) 57:493–8. doi:10.1016/j.tjog.2018.06.003

20. Santi D, Spaggiari G, Simonì M. Sperm DNA fragmentation index as a promising predictive tool for male infertility diagnosis and treatment management - meta-analyses. **Reprod BioMed Online** (2018) 37:315–28. doi:10.1016/j.rbmo.2018.06.023

21. Bie niek JM, Drabovich AP, Lo KC. Seminal biomarkers for the evaluation of male infertility. **Asian J Androl** (2016) 18:426–33. doi:10.1038/1008-682X.175781

22. Xu HY, Zhang MQ, Zhang HK, Wang LN, Li R, et al. Clinical Applications of Serum Anti-Mullerian Hormone Measurements in Both Males and Females: An Update. **Innovation** (2021) 2. doi:10.1016/j.innov.2021.100091

23. Faddy MJ, Gosen RG, Gosseon AD, Richardson SJ, Nelson JF. Accelerated disappearance of ovarian follicles in midlife - implications for forecasting menopause. **Hum Reprod** (1992) 7:1342–6. doi:10.1093/oxfordjournals.humrep.a137570

24. Gynecologists TACoOa. Committee opinion no. 618: Ovarian reserve testing. **Obstet Gynecol** (2015) 125:268–73. doi:10.1097/01.AOG.0000459864.68372.eC

25. Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WHB. A validated model of serum anti-mullerian hormone from conception to menopause. PloS One (2011) 6:e22024. doi:10.1371/journal.pone.0022024

26. Xu H, Feng G, Alpadi K, Han Y, Yang R, Chen L, et al. A model for predicting polycystic ovary syndrome using serum AMH, menstrual cycle length, body mass index and serum androstenedione in Chinese reproductive aged population: A retrospective cohort study. **Front Endocrinol (Lausanne)** (2022) 13:821368. doi:10.3389/fendo.2022.821368